Loading clinical trials...
Loading clinical trials...
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Conditions
Interventions
Ruxolitinib
Anagrelide
+2 more
Locations
26
United States
Mayo Clinic
Phoenix, Arizona, United States
Pacific Shores Medical Group
Long Beach, California, United States
University of Southern California
Los Angeles, California, United States
Ventura County Hematology-Oncology Specialists
Oxnard, California, United States
Compassionate Cancer Care Medical Group
Riverside, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
Start Date
November 14, 2017
Primary Completion Date
August 3, 2020
Completion Date
August 3, 2020
Last Updated
November 19, 2021
NCT03011372
NCT03144687
NCT02953704
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions